Pilot Study of an Educational Tool for Chronic Obstructive Pulmonary Disease (PUDDING)
The inadequate fulfillment of national targets for COPD described above indicates that interventions designed to increase adherence to recommendations in established guidelines could improve patient outcomes. This pilot study is therefore intended to indicate if a digital educational tool can increase adherence to COPD guidelines and measurably improve measures of disease control. If the objectives of the study are met, it provides a rationale for further developing the tool and validating it in controlled studies. This is an 8-week, single-arm pilot study in patients with COPD. A total of 35 patients will be included. Based on an anticipated screening failure rate of 50%, 70 patients will be screened. Patients will receive standard of care with a board-certified physician using an educational COPD tool.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Höllviken, Sweden, 23651
- Näsets läkargrupp, Prima Vård AB
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- COPD diagnosed at least 6 months prior to inclusion
- mMRC score of 2 or more at screening visit
Exclusion Criteria:
- Previous participation in this study. Participation is defined as informed consent.
- Currently participating in clinical trials for COPD.
- Ongoing oxygen treatment.
- Significant pulmonary disease other than COPD (e.g., asthma, lung fibrosis, sarcoidosis, interstitial lung disease, pulmonary hypertension, bronchiectasis, or Churg-Strauss syndrome, etc.).
- History of or planned pneumonectomy or lung volume reduction surgery.
- Patients participating in the acute phase of a pulmonary rehabilitation program, i.e., who started rehabilitation < 4 weeks prior to screening.
- Diagnosis of α-1 anti-trypsin deficiency.
- Ongoing treatment with oral corticosteroids for any indication.
- Treatment with systemic medication for COPD such as oral corticosteroids or monoclonal antibodies in the 28 days prior to screening.
- Heart failure NYHA Class III or IV.
- Acute myocardial infarction < 6 months from screening visit.
- TIA or stroke < 6 months from screening visit.
- Hospitalization for any CV or cerebrovascular event < 6 months from screening visit.
- Ongoing treatment for cancer.
- Other conditions that by the investigator's judgment cause remaining life expectancy to be less than a year.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intervention - treatment guided by digital tool
Intervention guided by the digital tool |
The intervention is that the treating physician will be guided by a digital tool describing treatment recommendations for COPD. The choice of treatment will be made by the investigator, based on his or her clinical judgment supplemented with support from the educational tool. All participating patients in the study will be treated by a physician that uses the tool. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
CAT score
Time Frame: 8 weeks
|
Change in COPD assessment test (CAT) score |
8 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
mMRC
Time Frame: 8 weeks
|
Change in mMRC (modified medical research council) score |
8 weeks
|
|
Walking distance
Time Frame: 8 weeks
|
Change in walking distance on a 6 minute walk test |
8 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2026-01001-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.